Abstract
Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
Keywords: Hypocalcemia, raloxifene, vitamin D deficiency.
Current Drug Safety
Title:Hypocalcemia Induced by Raloxifene
Volume: 7 Issue: 2
Author(s): Thuy D.T. Vu, Suresh Varadarajan, Ego Seeman, George Jerums and Richard J. MacIsaac
Affiliation:
Keywords: Hypocalcemia, raloxifene, vitamin D deficiency.
Abstract: Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
Export Options
About this article
Cite this article as:
D.T. Vu Thuy, Varadarajan Suresh, Seeman Ego, Jerums George and J. MacIsaac Richard, Hypocalcemia Induced by Raloxifene, Current Drug Safety 2012; 7 (2) . https://dx.doi.org/10.2174/157488612802715654
DOI https://dx.doi.org/10.2174/157488612802715654 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IL-22 and Its Receptors, New Players in the Inflammatory Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanotherapy Targeting the Tumor Microenvironment
Current Cancer Drug Targets Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials Human 5-HT4 and 5-HT7 Receptor Splice Variants: Are they Important?
Current Neuropharmacology Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs CYLD-Mediated Signaling and Diseases
Current Drug Targets Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design Biological Activities of Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Pleiotropic Functions of Rho GTPase Signaling: A Trojan Horse or Achilles Heel for Breast Cancer Treatment?
Current Drug Targets